Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment

Spine

Volumn 34, Issue 6, 2009, Pages 539-550

  Toth, Jeffrey M ^a   Boden, Scott D ^b   Burkus, J Kenneth ^c   Badura, Jeffrey M ^d   Peckham, Steven M ^d   McKay, William F ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUGHSTON CLINIC   (United States)

^d Medtronic Spinal and Biologics Business   (United States)

Author keywords

Bone resorption; Osteoblastic activity; Osteoclastic activity; Recombinant human bone morphogenetic protein 2 (rhBMP 2); Spinal fusion

Indexed keywords

COLLAGEN SPONGE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE RADIOGRAPHY; CANCELLOUS BONE; CELL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG IMPLANTATION; FEMALE; FRACTURE HEALING; HISTOLOGY; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SHEEP; TREATMENT RESPONSE; ANIMAL; BIODEGRADABLE IMPLANT; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DISEASE MODEL; FEMUR; HUMAN; PATHOLOGY; PHYSIOLOGY; RADIOGRAPHY;

ABSORBABLE IMPLANTS; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE RESORPTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR; FRACTURE HEALING; HUMANS; OSTEOCLASTS; RECOMBINANT PROTEINS; SHEEP; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65549116404     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181952695     Document Type: Article

References (51)

1. Urist MR, Strates BS. Bone morphogenetic protein. J Dent Res 1971;50: 1392-1406.
2. Urist MR, DeLange RJ, Finerman GA. Bone cell differentiation and growth factors. Science 1983;220:680-6.
3. Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003;85-A:1544-52.
4. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528 -34.
5. Sandhu HS, Kanim LEA, Kabo JM, et al. Evaluation of rhBMP-2 with an OPLA carrier in a canine posterolateral (transverse process) spinal fusion model. Spine 1995;20:2669-82.
6. Sandhu HS, Kanim LEA, Kabo MJ, et al. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996;21:2115-22.
7. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999;12: 179-86.
8. Hecht BP, Fischgrund JS, Herkowitz HN, et al. The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model. Spine 1999;24: 629-36.
9. Sandhu HS, Toth JM, Diwan AD, et al. Histologic evaluation of the efficacy of rhBMP-2 compared with autograft boneinsheep spinal anterior interbody fusion. Spine 2002;27:567-75.
10. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27 (suppl 1):S66-85.
11. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine 2002;27 (suppl 1):S26 -31.
12. Valentin-Opran A, Wozney J, Csimma C, et al. Clinical evaluation of recom-binant human bone morphogenetic protein-2. Clin Orthop Relat Res 2002; 395:110-20.
13. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 2003;55:1613-29.
14. Seeherman H, WozneyJ,Li R. Bone morphogenetic protein delivery systems. Spine 2002;27(suppl 1):S16-23.
15. Wozney JM. Overview of bone morphogenetic proteins. Spine 2002; 27(suppl 1):S2-8.
16. Hsu HP, Zanella JM, Peckham SM, et al. Comparing ectopic bone growth induced by rhBMP-2 on an absorbable collagen sponge in rat and rabbit models. J Orthop Res 2006;24:1660-9.
17. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphoge-netic proteins in the spine. Spine 2002;27(suppl 1):S40-8.
18. Anand N, Hamilton JF, Perri B, et al. Cantilever TLIF with structural allo-graft and rhBMP2 for correction and maintenance of segmental sagittal lordosis: long-term clinical, radiographic, and functional outcome. Spine 2006;31:E748-53.
19. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic pro-tein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 2003;28:1219-25.
20. Boden SD, Zdeblick TA, Sandhu HS, et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000;25:376-81.
21. Burkus JK. Bone morphogenetic proteins in anterior lumbar interbody fusion: old techniques and new technologies. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves. J Neuro-surg Spine 2004;1:254-60.
22. Burkus JK, Dorchak JD, Sanders DL. Radiographic assessment of interbody fusion using recombinant human bone morphogenetic protein type 2. Spine 2003;28:372-7.
23. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 2002;15:337-49.
24. Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 2003;16:113-22.
25. Burkus JK, Sandhu HS, Gornet MF. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine 2006;31:775-81.
26. Burkus JK, Sandhu HS, Gornet MF, et al. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 2005;87:1205-12.
27. Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J 2005;5(suppl 6):240S-9S.
28. Haid RW Jr, Branch CL Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004;4:527-38; discussion 538 -9.
29. Hansen SM, Sasso RC. Resorptive response of rhBMP2 simulating infection in an anterior lumbar interbody fusion with a femoral ring. J Spinal Disord Tech 2006;19:130-4.
30. Kleeman TJ, Ahn UM, Talbot-Kleeman A. Laparoscopic anterior lumbar interbody fusion with rhBMP-2: a prospective study of clinical and radio-graphic outcomes. Spine 2001;26:2751-6.
31. Lanman TH, Hopkins TJ. Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein-2 added to poly(L-lactide-co-D,L- lactide) bioresorbable implants. Neurosurg Focus 2004;16:E9.
32. Meisel HJ, Beier A, Hoell T, et al. Transient reduced mineral density associated with BMP-enhanced spinal fusion. [abstract] Proceedings of the NASS 20th Annual Meeting. Spine J 2005;55S-6S.
33. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004;1:19-23.
34. Resnick DK, Choudri TF, Dailey AT, et al. Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 16: bone graft extenders and substitutes. J Neurosurg Spine 2005;2:733- 6.
35. Sasso RC, LeHuec JC, Shaffrey C. Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J Spinal Disord Tech 2005;18 suppl:S77-81.
36. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone mor-phogenetic protein-2. J Neurosurg Spine 2005;3:436-43.
37. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006;19:483-6.
38. Pradhan BB, Bae HW, Dawson EG, et al. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine 2006;31:E277-84.
39. Gisep A, Wieling R, Bohner M, et al. Resorption patterns of calcium-phosphate cements in bone. J Biomed Mater Res A 2003;66:532-40.
40. Leniz P, Ripalda P, Forriol F. The incorporation of different sorts of cancellous bone graft and the reactionof the host bone.Ahistomorphometric study in sheep. Int Orthop 2004;28:2-6.
41. Nuss KM, Auer JA, Boos A, et al. An animal model in sheep for biocompatibility testing of biomaterials in cancellous bones. BMC Musculoskelet Disord 2006;7:67.
42. Walsh WR, Morberg P, Yu Y, et al. Response of a calcium sulfate bone graft substitute in a confined cancellous defect. Clin Orthop Relat Res 2003;406: 228-36.
43. Toth JM, Wang M, Scifert J, et al. Evaluation of 70/30 D,L-PLA for use as a resorbable interbody fusion cage. Orthopedics 2002;25:S1131-40.
44. Toth JM, Wang M, Estes BT, et al. Polyetheretherketone (PEEK) as a bio-material for spinal applications. Biomaterials 2006;27:324-34.
45. Kanatani M, Sugimoto T, Kaji H, et al. Stimulatory effect of bone morpho-genetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 1995;10:1681-90.
46. Kaneko H, Arakawa T, Mano H, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 2000;27:479-86.
47. Koide M, Murase Y, Yamato K, et al. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1 alpha through up-regulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 1999;259:97-102.
48. Miyaji H, Sugaya T, Kato K, et al. Dentin resorption and cementum-like tissue formation by bone morphogenetic protein application. J Periodontal Res 2006;41:311-5.
49. Wildemann B, Kadow-Romacker A, Lubberstedt M, et al. Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier. Calcif Tissue Int 2005;76:50-5.
50. Rodeo SA, Suzuki K, Deng X, et al. Use of recombinant human bone mor-phogenetic protein-2 to enhance tendon healing in a bone tunnel. Am J Sports Med 1999;27:476-88.
51. Sumner DR, Turner TM, Urban RM, et al. Locally delivered rhBMP-2 enhances bone ingrowth and gap healing in canine model. J Orthop Res 2004; 22:58-65.